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1. Introduction
Breast carcinoma is the most common cancer in women of reproductive age. In Europe and in
the United States, approximately 30% of all breast cancers occur before menopause and 15% of
women are diagnosed in the reproductive age (age of 45 or younger). Adjuvant chemotherapy
prolongs disease-free survival (DFS) and overall survival (OS), especially in young women,
but also induces long-term and severe side effects such as temporary or definitive ovarian
function suppression which results in potential loss of fertility and premature exposure
to the risks of menopause including cardiovascular diseases, osteoporosis, hot flashes
and genitourinary dysfunctions Bines et al. (1996). The probability of menopause with
chemotherapy depends on the type of regimen used and on the age of the patient. In the
literature, the estimated risk of amenorrhea varies between 0% and 60% in women younger
than 40 years and between 40% and 100% in women older than 40 years. Beyond age
and the type of regimen used, important variations reflect different durations of follow-up
and variable definitions of menopause and of chemotherapy-related amenorrhea Bines et al.
(1996).
2. Defining menopause status
The average age of menopause in women of Caucasian/European origin is around 51 years
Bines et al. (1996); Burger et al. (2007); Gracia et al. (2005); Welt et al. (2006). Pituitary
gonadotrophins stimulate ovarian steroid hormone production (estrogens, progesterone and
androgens). Estradiol [E2] Welt et al. (2006) and progesterone act via a negative feedback
loop to inhibit pituitary gonadotrophin release. Hormone release occurs on a cyclical basis
so that concentrations of follicle-stimulating hormone (FSH) peak in the mid-follicular phase
and decrease during the luteal phase, rising again shortly before menstruation Randolph et al.
(2006); Tanay & Fenton (2010). As E2 levels rise in the late follicular phase, concentrations
of luteinizing hormone (LH) surge (via positive feedback) in mid-cycle and then fall again
during the luteal phase (negative feedback) under the influence of progesterone and E2. Both
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2E2 and inhibin-B are under gonadotrophin influence. Both hormones are stimulated by FSH.
This allows the preservation of E2 secretion in the late reproductive phase Randolph et al.
(2006); Tanay & Fenton (2010); Welt et al. (2006). The decline in quality and quantity of
ovarian follicles (ovarian aging process) Broekmans et al. (2009); Burger et al. (2008) triggers
the hormonal and symptomatic changes of menopausal transition. This decline accelerates
around age 35 when the number of oocytes drops to approximately 25,000 (having been
approximately 300,000 at puberty). Anti-Müllerian hormone (AMH) Sowers et al. (2008); Yang
et al. (2011) produced by small preantral follicles is one of the earliest markers of ovarian
aging since it reflects the remaining pool of follicles. Compared with changes in FSH, LH,
progesterone, AMH and inhibin-B secretions, the fall in E2 levels occurs relatively close to
the menopause Welt et al. (2006). Before menopause, climacteric symptoms and bleeding
irregularities can occur as a consequence of changes in E2 and progesterone secretion.
Menopause is commonly defined as the last menstrual bleed or final menstrual period
(commonly named FMP). This can only be recognized retrospectively after 12 consecutive
months of amenorrhea. The FMP is typically preceded by a period of hormonal instability
and irregularity in the menstrual cycle lasting up to several years. In the literature, there is no
uniform definition of when this transitional period also called “perimenopause” begins.
However, different criteria (such as the first occurrence of more than 7 days difference in
cycle length) have been proposed. Perimenopause extends until the 12 month-period of
amenorrhea has elapsed. Prior to FMP, bleeding patterns are highly unpredictable, vasomotor
symptoms are common but not present in all cases. There is no hormonal marker which
infallibly signals permanent cessation of menstruation. In 2001, the stages of reproductive
aging workshop proposed FSH Burger et al. (2007); Randolph et al. (2006) as the best marker
available but did not establish levels that defined the menopause. FSH secretion itself is
variable. Elevations may occur up to 10 years before the menopausal transition. Furthermore,
there is a lack of agreement between assays, and body size and age have effects independent
of menstrual status. Based on changes in menstrual cycles and levels of FSH, the first
standardized classification of stages or reproductive aging workshop (STRAW) was proposed
in 2001Soules et al. (2001). This classification includes 7 stages. These stages take into account
not only the changes in bleeding patterns but also the changes in hormone levels. AMH
could be of potential use in better defining the stages of menopausal transition. However, its
widespread use has been precluded by cost and the lack of sensitivity and reproducibility of
available assaysLedger (2010). According to the most recent National Comprehensive Cancer
Network (NCCN) guidelines Guidelines (2010) on the management of breast cancer, a woman
can reasonably be considered postmenopausal if any of the following conditions have been
fulfilled :
• She has had prior bilateral oophorectomy.
• She is age 60 years or older.
• If less than 60, she has had amenorrhea of 1 year or longer in the absence of chemotherapy,
tamoxifen, toremifene or ovarian suppression, and FSH and E2 levels are in the
postmenopausal range.
• If she is taking tamoxifen or toremifene and is under 60 years of age, FSH and E2 levels are
in the postmenopausal range.
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The guidelines mention that it is not possible to determine menopausal status when a woman
is taking a GnRH agonist or antagonist. If none of these conditions are fulfilled and yet the
patient has infrequent or no menses, she should be considered pre- or perimenopausal.
3. Defining chemotherapy-related amenorrhea
In premenopausal patients, chemotherapy can induce temporary or permanent ovarian
dysfunction Meirow (2000); Valagussa et al. (1993); Walshe et al. (2006).
The definition of CRA is not consistent across the literature and this helps explain the wide
range in reported rates among chemotherapy trials Bines et al. (1996); Walshe et al. (2006).
According to the American College of Obstetricans and Gynecologists, chemotherapy-related
amenorrhea is defined as cessation of menses for 6 months. However other authors have
defined CRA as the cessation of menses lasting 3 to 6 months or longer, or used the criterion of
menstrual cessation lasting at least 12 months. Other difficulties are explained by the fact that
inconsistencies exist in the way amenorrhea is reported. Some authors report the incidence
of amenorrhea immediately upon completion of chemotherapy, while others select various
time points after the start and end of chemotherapy Meirow (2000); Valagussa et al. (1993);
Vegetti et al. (2000). The time point most commonly encountered in the literature is 12 months
after the end of chemotherapy. Chemotherapy-related amenorrhea is generally linked to the
patient’s age as well as treatment protocol (types of chemotherapeutic agents used, doses
and schedules) Bonadonna et al. (2005); Goldhirsch et al. (1990); Padmanabhan et al. (1986);
Valagussa et al. (1993); Warne et al. (1973). Data on ovarian function are widely available
for certain regimens, such as cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
polychemotherapy Bonadonna et al. (2005); Goldhirsch et al. (1990); Warne et al. (1973) and
anthracycline-based treatments Hortobagyi et al. (1986); Levine et al. (1998); Pritchard et al.
(2005); Roche et al. (2006), but fewer studies have been conducted on taxane-based regimens
Abusief et al. (2006); Berlière et al. (2008); Clemons & Simmons (2007); Davis et al. (2005);
Fornier et al. (2005); Martin et al. (2003; 2005); Tham et al. (2007), and they unfortunately show
contradictory results. Other problems can be summarized by the lack of prospective studies
and by the limited duration of follow-up.
4. Rates of chemotherapy-related amenorrhea with main cytotoxic agents
4.1 Cyclophosphamide-based regimens Bonadonna et al. (2005); Goldhirsch et al. (1990);
Warne et al. (1973)
As previously mentioned, the incidence of ovarian dysfunction is related to patient age,
the specific agents used and the total dose administered, especially the dose of alkyaling
agents such as cyclophosphamide. Amenorrhea rates following combination chemotherapy
consisting of CMF regimens range from 21% to 71% in women aged 40 years and younger,
and from 40% to 100% in older ones Bonadonna et al. (2005); Goldhirsch et al. (1990);
Padmanabhan et al. (1986); Warne et al. (1973). In the interpretation of the data with CMF
regimens, many difficulties exist due to a lack of homogeneity of CMF regimens: variations
in the doses and type of administration of cyclophosphamide (oral vs. intravenous) and
variations in the total number of courses: 3 to 12 courses. In a manuscript dedicated to
“30 years follow-up of randomized studies of adjuvant CMF in operable breast cancer”,
Bonadonna at al. Bonadonna et al. (2005) defined drug-induced amenorrhea as “the
irreversible cessation ofmenstrual periods during chemotherapy treatment or in the first years
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4of follow-up, in the absence of disease relapse”. Amenorrhea rates were mentioned for 12
versus 6 cycles of CMF. CMF regimen consisted of cyclophosphamide (100 mg/m2)/orally
from day 1 to day 14, methotrexate (40 mg/m2) intravenously on day 1 and 8, and
5-fluorouracil (600 mg/m2) every 4 weeks. The incidence of iatrogenic amenorrhea was
reported in the two regimens (6 cycles versus 12 cycles) by age group. Overall, drug-induced
amenorrhea was reported more often in the longer regimen (75% versus 62%) than in the
shorter one. In women younger than 45 years, the incidence of amenorrhea was 52.3%
in the longer regimen vs. 31% in the shorter regimen. However, in women aged 45 or
older, the incidence of amenorrhea was unrelated to the duration of treatment (97% vs.
96%). Unfortunately, only few investigators have considered the fact that chemotherapy may
cause incomplete ovarian damage resulting in premature menopause months or years after
completion of treatment.
4.2 Doxorubicin-based regimens Hortobagyi et al. (1986); Levine et al. (1998); Roche et al.
(2006)
The association of doxorubicin with amenorrhea and infertility was initially
debatableHortobagyi et al. (1986); Levine et al. (1998). Bines et al. Bines et al. (1996)
reported an amenorrhea rate of 34% after therapy with adriamycin and cyclophosphamide
(AC). However, these authors did not differentiate between younger and older women. A
Canadian adjuvant trial (NCIC CTG MA5) Pritchard et al. (2005) that compared 6 courses
of CMF (Standard Bonadonna regimen) (cyclophosphamide 100 mg/m2orally days 1
through 15, methotrexate 40 mg/m2Gracia et al. (2005) intraveinously days 1 and 8 and
fluorouracil 60 mg/m2Gracia et al. (2005) intraveinously days 1 and 8) with 6 courses of
intensive CEF (cyclophosphamide 75 mg/m2Gracia et al. (2005) orally days 1 through 14,
epiadriamycin 60 mg/m2Gracia et al. (2005) intraveinously days 1 and 8 and fluorouracil 500
mg/m2intraveinously day 1 and 8) reported that the incidence of CRA was slightly higher in
the CEF arm (51%) than in the CMF arm (42.6%). This difference was observed at 6 months
but no difference was observed at 12 months. An interesting conclusion of this study is that
late chemotherapy-induced amenorrhea (amenorrhea at 12 months) seems to be associated
with improved outcome in premenopausal patients with receptor-positive breast cancer.
4.3 TaxanesAbusief et al. (2006); Berlière et al. (2008); Clemons & Simmons (2007); Davis
et al. (2005); Fornier et al. (2005); Martin et al. (2003; 2005); Tham et al. (2007)
Taxanes, including paclitaxel and docetaxel, have recently been introduced in the adjuvant
setting of breast carcinoma, based on Phase III data with adjuvant anthracycline and
taxane combinations or sequences demonstrating significant benefits compared with non
taxane-containing regimensClemons & Simmons (2007); Davis et al. (2005); Fornier et al.
(2005); Martin et al. (2003); Roche et al. (2006); Tham et al. (2007). The rates of
chemotherapy-induced amenorrhea associated with taxane-based regimens reported by
different studies are discordant. Since taxanes are administered either sequentially or
concurrently with anthracyclines and cyclophosphamide, it is difficult to evaluate the true
impact of taxanes on the development of amenorrhea.
Breast Cancer International Research Group (BCIRG) Trial 001 Martin et al. (2003; 2005)
reported an incidence of amenorrhea after adjuvant docetaxel 75 mg/m 2, doxorubicin 50
mg/m2and cyclophosphamide 500 mg/m2(TAC) 6 courses every 3 weeks or 5-fluorouracil
500 mg/m 2, doxorubicin 50 mg/m2and cyclophosphamide 500 mg/m2(FAC) of 51.4%
16 Amenorrhea
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and 32.8%, respectively and the latest update of this trial presented at the San Antonio
Breast Cancer Symposium in 2010 with a longer follow-up confirmed these results: 47% of
amenorrhea in the TAC group versus 30% in the FAC group (median follow-up 10 years).
In the study by Fornier Fornier et al. (2005), 166 very young patients were reviewed. All
patients were treated with AC (doxorubicin at a dose of 60 mg/m 2 + cyclophosphamide
at a dose of 600 mg/m2for 4 cycles followed by a taxane). The majority of patients were
given AC followed by paclitaxel at a dose of 175 mg/m 2 for 4 cycles administered every
2 - 3 weeks. Only 7 patients received docetaxel (100 mg/m2). In this cohort, long-term
amenorrhea was defined as the absence of menstruations> 12 months after the completion of
all chemotherapy. No hormone values were available and the conclusions of this study were
that addition of a taxane did not appear to produce a higher rate of chemotherapy-related
amenorrhea compared to historical controls.
In the study by Davis et al. Davis et al. (2005), 159 premenopausal patients were reviewed.
As initial chemotherapy, 102 women received AC (doxorubicin - cyclophosphamide),
39 received CMF (cyclophosphamide – methotrexate-fluorouracil) and 18 received CAF
(cyclophosphamide - doxorubicin - 5-fluorouracil). Following the initial regimen, 51 patients
received additional adjuvant chemotherapy, generally with a taxane for 12 weeks (paclitaxel
in 32 patients and docetaxel in 19 patients). The conclusions of this study were similar to
those of Fornier et al. Fornier et al. (2005): sequential addition of taxanes did not appear to
increase the risk of chemotherapy-induced amenorrhea, when added to a non-taxane regimen.
Moreover, authors did not find any impact of the type of initial chemotherapy administered.
Unfortunately, in this study, no hormone values were available.
More recently, Tham et al. Tham et al. (2007) published a study involving 191 patients
(including 158 patients < 40 years of age at the start of chemotherapy). The patients received
4 cycles of AC alone or followed by a taxane. There was no stratification between paclitaxel
and docetaxel. The definition of CRAwas a little different in this study. Indeed, it was defined
as cessation of menses within 1 year of starting chemotherapy and lasting > 6 months.
In a subgroup of young patients (< 40 years), addition of a taxane resulted in a higher
incidence of CRA (61% versus 44%). In women over 40 years of age, amenorrhea rates were
high in both the group of AC alone and the group of AC followed by a taxane (81% versus
85%). No statistically significant difference was observed between the two groups.
Our team and the team of Toulouse Berlière et al. (2008); Roche et al. (2006) conducted
a substudy with patients included in the PACS 01 study. The main objective of our
retrospective study was to evaluate the incidence of reversible chemotherapy-related
amenorrhea in patients treated with 6FEC (5-fluorouracil 500 mg/m2, epirubicin 100
mg/m2and cyclophosphamide 500 mg/m2) and 3FEC/3D (3 FEC followed by 3 docetaxel
100 mg/m 2), and the impact of sequential docetaxel on the rate of CRA. The incidence of
CRA at the end of chemotherapy was similar in the 2 groups: 93% in the 6FEC arm and 92.8%
in the 3FEC/3D arm. However, in the year following the end of chemotherapy, more patients
recovered menses in the 3FEC/3D arm than in the 6FEC arm: 35% versus 23.7% (p=0.019).
Among the patients for whom hormone values were available, 43% in the 3FEC/3D arm and
29% in the 6FEC arm showed premenopausal levels one year after the end of chemotherapy
(p<0.01).
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65. Prognostic impact of chemotherapy-related amenorrhea
Whether or not induction of amenorrhea by cytotoxic chemotherapy (34-44) is a prognostic
factor in the treatment of premenopausal women is still controversial. A positive impact on
DFS was found by some Aebi et al. (2000); Borde et al. (2003); Brincker et al. (1987); Del Mastro
et al. (1997); Parulekar et al. (2005); Poikonen et al. (2000); Powles (1998); Swain et al. (2010)
but not confirmed by others Ferretti et al. (2006); Vanhuyse et al. (2005). Del Mastro et al
Del Mastro et al. (1997) conducted a review of 13 studies involving 3929 patients undergoing
CMF-based regimens, with follow- up ranging from 3 to 20 years. A statistically significant
association was found between the development of chemotherapy-related amenorrhea and
DFS. In the majority of cases, OS was found to be associated with amenorrhea (in 3 out
of 5 studies reviewed). In a study recently published by Parulekar et al. Parulekar et al.
(2005), similar results were observed with intensive CEF (cyclophosphamide, epirubicin,
5-fluorouracil therapy), which induced a higher rate of amenorrhea than the classic CMF
protocol, but OS was also better in the CEF arm than in the CMF arm.
In the Trial VI study by the International Breast Cancer Study Group (IBCSG)Goldhirsch
et al. (1990) cessation of menses, even for a limited time period, appeared to be beneficial,
especially in patients with ER-positive breast tumors. In this study, however, the greatest effect
was observed in patients receiving suboptimal treatment with only 3 initial CMF courses.
Bonadonna et al.Pagani et al. (1998) exhibits a different point of view. Their analysis of
the influence of drug-induced amenorrhea on the therapeutic outcome after CMF treatment
refutes the hypothesis that adjuvant chemotherapy acts merely as chemical castration. As
reported in many individual trials and the worldwide overview, adjuvant chemotherapy
benefits hormone-responsive and hormone-unresponsive tumors, whereas endocrine therapy
has no worthwhile benefit in E2 receptor-negative subpopulations. Bonadonna et al.
Bonadonna et al. (2005) estimates that adjuvant chemotherapy has cytotoxic effects regardless
of the putative hormone dependency of the tumor cells.
In the PACS 01 trial Roche et al. (2006), a survival advantage in favor of the 3FEC/3D arm
was observed only for women aged over 50 years, but not for the younger population. The
reason for this is unclear but the impact of reversible amenorrhea needs to be investigated
further, since our small retrospective analysis suggests that amenorrhea Berlière et al. (2008)
was correlated with DFS in the 3FEC/3D group. In the NSABP B30 trialGanz et al. (2011),
5531 breast cancer patients were randomly assigned to sequential doxorubicin (A) 20 mg/m
2 + cyclophosphamide (C) 600 mg/m 2 4 courses every 3 weeks followed by docetaxel (T)
100 mg/m24 courses every 3 weeks, or concurrent TAC (docetaxel 75 mg/m2, doxorubicin
50 mg/m2and cyclophosphamide 500 mg/m24 courses every 3 weeks) or 4 cycles of AT
(doxocuribin 50 mg/m 2 + docetaxel 75 mg/m 2 every 3 weeks). Tamoxifen was administered
in all patients with E2 hormone receptor positive tumors. The results indicated that patients
with more than 6 months amenorrhea had a better prognosis than patients with a shorter
period of amenorrhea.
6. Assessing post-chemotherapy ovarian function
Assessing post-chemotherapy ovarian function in breast cancer survivors of late reproductive
age is important to clinical decision making on a range of issues such as choice of endocrine
therapy Berlière et al. (2010); Ganz et al. (2011); Su (2010). It is therefore important to analyze
the different available tools.
18 Amenorrhea
www.intechopen.com
Chemotherapy-Related Amenorrhea in Breast Cancer: Review of the Main Published Studies, Biomarkers of Ovarian Function and Mechanisms Involved in Ovarian Toxicity 7
Currently, the primary tool for assessing post-chemotherapy ovarian function is menstrual
pattern. However, in patients who received chemotherapy and endocrine therapy, lack of
menses does not always represent ovarian failure.
In an abstract presented in poster form at the San Antonio Breast Cancer Symposium in 2010
Berlière et al. (2010), we reported the results of a prospective study conducted in our Breast
Clinic between 1999 and 2003, comparing ovarian function between premenopausal breast
cancer patients receiving tamoxifen alone (group I) and those receiving tamoxifen following
chemotherapy (group II). 138 premenopausal patients, treated for early breast cancer were
included: 68 patients in the group of tamoxifen alone and 70 patients in the group of tamoxifen
administered after chemotherapy (6 cycles of FEC 100 on day 1 every 3 weeks – 5- fluorouracil
500 mg/m2, epirubicin 100 mg/m2and cyclophosphamide 500 mg/m 2 – or 4 cycles of EC on
day 1 every 3 weeks – epiadriamycin 75 mg/m 2 and cyclophosphamide 500 mg/m2). All
patients had a confirmed premenopausal status (biological data) at the entry of the study or 3
months later. Three patients were out of study in groups I and 2 were out of study in group
II. The results of this prospective study were analyzed at the end of 2009. We identified 4
different ovarian patterns of response to tamoxifen in the 2 groups:
1. regular menses (> 10 cycles/year)
2. oligomenorrhea (5 to 9 cycles/year)
3. severe oligomenorrhea(1 to 4 cycles/year)
4. complete amenorrhea.
The number of patients in each subgroup was respectively
• for group I (65 patients): 3 (4%), 19 (29%), 38 (58%) and 5 (8%)
• for group II (68 patients): 2 (3%), 21 (30%), 38 (55%) and 7 (10%).
We confirmed that amenorrhea is an insufficient parameter to define menopausal status in
patients receiving tamoxifen. The most common biomarkers used are FSH and E2. Low E2
levels are also insufficient to define menopause because while on tamoxifen therapy patients
can exhibit low E2 levels, low FSH levels and oligomenorrhea. These data are very important
in the choice of endocrine therapy.
Measurement of ovarian reserve in breast cancer survivors may increase understanding of a
woman’s reproductive potential after cancer chemotherapy Partridge et al. (2008; 2010); Su
(2010). Reproductive potential is generally related both to the quantity and quality of ovarian
primordial follicles. Several other markers of ovarian reserve have been evaluated including
early follicular phase serum E2, FSH, AMH and inhibin-B as well as measurements of antral
follicle count (AFC) and ovarian volume. The interesting study of Partridge et al. Partridge
et al. (2010) confirms that young breast cancer survivors who have undergone cytotoxic
chemotherapy and remain premenopausal have diminished AFC levels when compared
with healthy controls. This study also reveals that a lower level of AMH appears to be
the best serum predictor of diminished AFC Partridge et al. (2008; 2010), which is thought
to reflect reduced likelihood of future pregnancy. AMH, the anti-Müllerian hormone, is a
member of the transforming growth factor β (TGFβ) family and is produced by FSH-sensitive
early antral follicles. In this way, it may be a more sensitive predictor of ovarian reserve
than other markers, such as AFC and inhibin-B, which detect more mature primordial
follicles. Some studies exhibit interesting results Anderson & Cameron (2011); Domingues
et al. (2010); Knauff et al. (2009); Rosendahl et al. (2010); Yu et al. (2010). In the study of
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8Partridge Domingues et al. (2010); Partridge et al. (2010), AFC and AMH seem to be the
best markers of ovarian reserve. These two markers are highly correlated and for breast
cancer patients receiving tamoxifen, lower AFC, AMH and inhibin-B were observed than for
non-tamoxifen-treated survivors.
However, it is important to insist on the fact that breast cancer survivors can become pregnant
with undetectable levels of AMH Anderson & Cameron (2011). In our institution, this
year and the year before, 4 patients (30, 39, 36 and 30 years respectively) became pregnant
with undetectable levels of AMH, but we have no values before the start of chemotherapy.
Some variations of AMH while on metformin, tamoxifen and aromatase inhibitors have been
described Cordes et al. (2010); Dieudonné et al. (2011); Panidis et al. (2010).
In conclusion, AMH seems to be themost interesting biological marker but further prospective
studies are needed to evaluate the exact value of the different markers (AFC, AMH and
inhibin-B). In the future, women interested in post-treatment fertility may be able to undergo
ovarian reserve testing before and upon completion of systemic therapy. Prospective studies
are needed to determine the predictive values of these tests for pregnancy after chemotherapy
as well as the potential value in predicting premature menopause in young cancer survivors.
Quality of life outcomes also need to be investigated prospectively Knobfm (2006).
7. Mechanisms of ovarian injury
The follicular reserve within the ovaries consists mainly of quiescent primordial follicles
developed during fetal life. A tremendous number of primordial follicles will be annihilated
before or shortly after birth and throughout postnatal life by a physiological programmed
cell death process named apoptosis Faddy & Gosden (1995). This physiological cellular
machinery may predispose the follicles to apoptosis induced by exogenous signals, such as
chemotherapeutic agents. The first histological study performed on human ovaries after
chemotherapy Browne et al. (2011); Meirow et al. (2007; 1999) demonstrated that the end
result of chemotherapy was ovarian atrophy and global loss of primordial follicles. But the
effect of chemotherapy on the ovary is not an “all or nothing phenomenon”. The mechanisms
involved in the loss of primordial follicles in response to anticancer therapy are not well
understood. A few human and animal studies Faddy & Gosden (1995); Meirow et al. (1999)
demonstrated that chemotherapy-induced damage to ovarian pregranulosa cells and that
apoptosis occurred during oocyte and follicle loss.
The results of a study conducted by Meirow et al. Meirow et al. (2007) indicate that injury
to blood vessels and focal fibrosis of the ovarian cortex are present in ovaries of patients
previously exposed to chemotherapy. These modes of injury were present in non-atrophic
ovaries of patients that were not sterilized by chemotherapy.
Ben Aharon and his coworkers Ben-Aharon et al. (2010) evaluated the effects of doxocuribin
(injected intraperitoneally) on mice ovaries. A single injection of doxorubicin resulted in a
major reduction in both ovarian size and weight that lasted even one month post-treatment.
A dramatic reduction in ovulation rate was also observed one week after treatment, followed
by a partial recovery at one month. In an attempt to characterize the apoptotic effect of
doxorubicin on the ovary, the authors were able to detect apoptosis in histological sections of
mice ovaries by depicting caspase-3 activity and TUNEL staining. The authors observed in the
doxorubicin-treated mice a loss of premature follicles as well as perivascular changes already
20 Amenorrhea
www.intechopen.com
Chemotherapy-Related Amenorrhea in Breast Cancer: Review of the Main Published Studies, Biomarkers of Ovarian Function and Mechanisms Involved in Ovarian Toxicity 9
described in human ovaries following administration of other chemotherapeutic agents such
a cyclophosphamide and cisplatin Browne et al. (2011); Meirow et al. (1999).
In a study conducted in our laboratory, mice were injected intraperitoneally with a single dose
of cyclophosphamide (200 mg/kg). These experiments did not allow us to identify an increase
of apoptosis in mice ovaries treated with cyclophosphamide.
Other previous studies also showed that a single dose of cyclophosphamide was not
associated with an increased rate of apoptosis. This is why in our laboratory, we will repeat
the injections of cyclophosphamide in new experiments to try to observe apoptosis in mice
ovaries.
The studies of Meirow et al. Meirow et al. (2007) and Aharon Ben-Aharon et al. (2010)
hypothesized a combined mechanism of neovascularization and ovarian tissue scarring with
a direct toxic effect on the primordial follicles.
Personally, we think that additional processes that lead to ovarian damage and follicles
loss after chemotherapy may be involved such as vascular complications and ischemic
mechanisms. We have also planned to investigate these mechanisms on mice ovaries. Other
drugs such as taxanes need also to be studied to elucidate ovarian toxicity of modern drugs
and to give accurate information to young breast cancer patients.
8. Conclusion
This chapter was written after review of the literature (Pubmed research) and after analysis of
personal data (PACS 01 substudy, evaluation of ovarian function while on tamoxifen, personal
laboratory experiments). Our review highlights important difficulties:
• The definition of chemotherapy-related amenorrhea suffers from a lack of uniformity in
the literature.
• Many studies are retrospective and evaluate old chemotherapy regimens. In the
prospective studies, the duration of follow-up is too short and very often limited to
anamnestic data.
• We thus recommend a prospective evaluation of endocrine function before chemotherapy
and after treatment completion, and in this context we have initiated a multicentric
prospective study. Follow-up has to last for a very long time (10 years minimum).
• The impact of taxanes on ovarian function requires further studies and laboratory studies.
Correct estimation of the risk of menopause and possibilities for preserving fertility according
to age and treatment will facilitate the decision-making process regarding adjuvant therapy in
breast cancer. This process requires precise information andwill enable each patient to balance
the potential benefits of treatment against the potential adverse effects and future risk.
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